Cumberland Pharmaceuticals Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release



Cumberland Pharmaceuticals Expands into Oncology Support

FDA-approved Ethyol® and Totect® address harmful effects of cancer treatments to help improve the quality of life for oncology patients

NASHVILLE, Tenn., April 9, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals - announced today that it has expanded its medical specialties to include oncology-related medications. The company's entry into the oncology specialty includes two initial supportive care medications: Ethyol® (amifostine) injection and Totect® (dexrazoxane hydrochloride) injection.  

ETHYOL® (AMIFOSTINE)

"Since the company's founding, Cumberland has endeavored to deliver high quality medicines to improve patient care," said CEO AJ Kazimi. "Our strategy has been to focus on select medical specialties that we can support nationally and make a significant impact. Oncology is a particularly rewarding and valuable field, and we are delighted to be able to help patients as they undergo their cancer treatments."

There were 1,688,780 new cases of cancer diagnosed in the U.S. in 2017, and advances in treatment have resulted in the average patient now living longer after initial diagnosis. As a result, quality of life becomes of paramount concern - and Cumberland's focus is on supporting cancer patients during their treatment, with the goal of improving their ongoing quality of life.

"The overarching goal of supportive care is to help patients tolerate and continue their cancer treatments," said Kazimi. "Our oncology medications enable us to target the side effects of patients' cancer treatments and help address the psychological or social problems that might result from those complications. We're grateful for the opportunity to contribute to the welfare of cancer patients, and help improve their quality of life."

Cumberland entered into an exclusive U.S.  license to distribute and market both Ethyol and Totect with the Clinigen Group plc, a British specialty pharmaceutical and services company following a Strategic Alliance established between the companies.

Ethyol® and Totect® can offer significant benefits to cancer patients as noted in the following: 

ETHYOL® (AMIFOSTINE)

For more information, including full prescribing instructions, please visit www.ethyol.com       

TOTECT® (DEXRAZOXANE)

For more information, including full prescribing instructions, please visit www.totect.com

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. The Company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology, and oncology market segments.

The Company's portfolio of FDA approved brands includes:

Cumberland's pipeline of product candidates includes:

For more information on Cumberland's approved products, including full prescribing instructions, please visit the individual product websites, links to which can be found on the Company's website www.cumberlandpharma.com.

TOTECT® (DEXRAZOXANE)

Cumberland Pharmaceuticals Logo (PRNewsfoto/Cumberland Pharmaceuticals Inc.)

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-expands-into-oncology-support-300626218.html

SOURCE Cumberland Pharmaceuticals Inc.

News Provided by Acquire Media

Close window | Back to top